Firefly Neuroscience, Inc. (AIFF)

Firefly Neuroscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	2023	2022	2021
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.06	0.5	-	0.03
Gross Profit	0.06	0.5	-	0.03
Selling, General & Admin	3.57	2.84	1.98	1.76
Research & Development	1.06	0.74	1.27	2.93
Operating Expenses	4.63	3.58	3.25	4.69
Operating Income	-4.56	-3.08	-3.25	-4.65
Interest Expense	-0.02	-0.02	-0.57	-0.14
Currency Exchange Gain (Loss)	0.04	0.04	-	-
Other Non Operating Income (Expenses)	0.43	0.46	0.01	-0
EBT Excluding Unusual Items	-4.11	-2.6	-3.82	-4.79
Gain (Loss) on Sale of Investments	-	-	-	0.55
Gain (Loss) on Sale of Assets	-	-	0.17	0.31
Asset Writedown	-	-	-0.08	-
Other Unusual Items	-	-	-0.06	-0.45
Pretax Income	-4.11	-2.6	-3.79	-4.38
Income Tax Expense	0	0	-	-
Net Income	-4.11	-2.6	-3.79	-4.38
Net Income to Common	-4.11	-2.6	-3.79	-4.38
Shares Outstanding (Basic)	43	31	2	-
Shares Outstanding (Diluted)	43	31	2	-
Shares Change (YoY)	1773.86%	1264.45%	-	-
EPS (Basic)	-0.10	-0.08	-1.66	-
EPS (Diluted)	-0.10	-0.08	-1.66	-
Free Cash Flow	-3.72	-2.17	-2.89	-3.82
Free Cash Flow Per Share	-0.09	-0.07	-1.27	-
Gross Margin	100.00%	100.00%	-	100.00%
Operating Margin	-7131.25%	-618.07%	-	-14543.75%
Profit Margin	-6426.56%	-522.69%	-	-13690.63%
Free Cash Flow Margin	-5809.38%	-436.14%	-	-11937.50%
EBITDA	-4.55	-3.06	-3.24	-4.23
D&A For EBITDA	0.01	0.01	0.01	0.43
EBIT	-4.56	-3.08	-3.25	-4.65

Source: S&P Capital IQ. Standard template. Financial Sources.